Meanwhile on the Personnel side of things, Centerpulse & then Zimmer has been involved. This does not represent an exhaustive list of personnel connected between the two companies, only to highlight that someone connected to Zimmer (before it Centerpulse) has been at the helm of Sintx since its founding.
That makes Personnel connected to Zimmer Product R&D connected to Biomet Chief external scientific researcher connected to Biomet. Zimmer + Biomet = Zimmer Biomet June 2015
Founded 1996
Dr. Hofmann, MD
Centerpulse Orthopedics Inc., an Austin-based subsidiary of Switzerland-based Centerpulse AG [NYSE: CEP], on Tuesday unveiled the Natural-Knee Unicompartmental System Instrumentation for partial replacement of the knee joint. Dr. Aaron Hofmann, an orthopedic surgeon at the University of Utah Medical Center who helped design the Natural-Knee system
Oct 2003
Dr. Max Link, PHD (Chairman 2003-2014)
The above quote was from Sintx first attempt to IPO in 2007. Now im going to reference another blurb about Dr Link from the 2014 IPO fillings. Notice anything missing?
Looks like, for some reason, connections between Sintx and Zimmer was purposefully withheld in the 2014 IPO paperwork. Also, in the description of current CEO Dr. Bal, there is no mention of him being a surgeon designer for Zimmer the way this fact was mentioned about Dr. Hofmann on the 2007 IPO paperwork. This despite Dr. Bal's extensive resume showing him as such. Ive included other supportive evidence showing he was a paid consultant for Zimmer. Why do you think this information was withheld at IPO? Certainly if Sintx was a scam, as some like to claim, it would have leaned harder on this information instead of hiding it wouldnt you think?
2012 - Dr Sonny Bal, MD joins Sintx board of directors
My old link to Dr Bal's 2013 resume experienced a 404 error. Fortunately i found a working link and archived it this time.
========================================
Now ive been purposefully censored on this board being limited to 3 posts a day for months now. So see you tomorrow. Almost like someone does not want the truth out? Too bad for them it just forced me to consolidate information.
========================================
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
The only evidence of a product being created with a strategic partner is a hip implant with Biomet, a Zimmer Biomet company. I have often used Zimmer and ZB to represent Zimmer Biomet as i see Zimmer Biomet as just a continuation of Zimmer. However legally these are 3 different entities with Zimmer and Biomet being child corporations of Zimmer Biomet Holdings. A strategic partnership with one is a strategic partnership with all imo.
You have Sintx MC2 femoral head articulating against Biomet's E1 liner. You have Si3N4 coating on Biomets G7 shell. Whats left to disclose for this product to move forward is how the femoral stem will be made. Will it be made of a metal material with coating or will it be made of a 3D printed porous Si3N4? I lean toward 3D printed porous stem because, as disclosed in a recent presentation, there is renewed interest in Sintx femoral head and coating tech for a shell after disclosure of further refining of 3d printing. As the studies made to date only indicate a product in development with Biomet IP, that really only leaves 1 company as a possible source for this renewed interest...Zimmer Biomet family of companies.
Anyone that completely ignores or disregards the information is not to be trusted. Anyone that uses legal loopholes to misrepresent connections between companies is not to be trusted. The information laid out is extensively sourced and left for the reader to decide. I would love help in further refining the information ive presented so its as accurate as possible, sadly no one is interested in truth...at least publicly. The only interest ive seen is using a small truth to drive a very different narrative that seems to distract from this truth. Stockprices can be manipulated by a cabal of persons (persons being individuals and companies). Theses business dealings cannot. They either are or are not. In this particular case, the dealings go back 17 years at least on the R&D front and go back to the beginning of Sintx on the personnel side of things.
Large companies use small companies to derisk technology and acquire it. Thats the simplest most straightforward explanation. However as shown by Eli Lilly strategic partnership with Amylin, reality is not always as straightforward. Still while Eli Lilly did not acquire Amylin in the end, it used Amylin for its benefit. Thats what i expect Zimmer Biomet to do with Sintx, for it to use Sintx for its benefit. It was a Win/Win for Eli/Amylin stakeholders and I expect that here too.
========================================
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application